The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

Characteristics of study subjects. by Jung Eun Choi (563339)

“…There was a significant decrease in the concentration of free T3 in girls with higher BPA concentrations.…”

Data for Fig 1. by Rachael M. Giersch (22331947)

“…We also observe a significant decrease in survival in animals that progress to >10% cancer in their hemolymph, while we see no effect on survival in clams with BTN that are long-term non-progressors. …”

Grade system. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Literature search. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Study characteristics. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Flowchart of literature retrieval. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Data extraction. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”

Cochrane Collaboration’s risk of bias tool. by Zhuoyang Xia (21354186)

“…We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. …”